Age-Related Macular Degeneration

Ophthalmology
28
Pipeline Programs
17
Companies
44
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
5
4
9
1
6
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
788%
Small Molecule
113%
+ 33 programs with unclassified modality

Competitive Landscape

16 companies ranked by most advanced pipeline stage

Novartis
NovartisBASEL, Switzerland
4 programs
2
2
Ranibizumab 0.5 mgPhase 41 trial
Verteporfin for injectionPhase 41 trial
IptacopanPhase 21 trial
VisudynePhase 21 trial
Active Trials
NCT05230537Active Not Recruiting170Est. Oct 2026
NCT00140803Completed106Est. Jan 2007
NCT02130024Completed281Est. Nov 2017
+1 more trials
Bausch + Lomb
Bausch + LombNJ - Bridgewater
1 program
1
pegaptanib sodium injectionPhase 41 trial
Active Trials
NCT01573572Completed131Est. Nov 2019
Astellas
AstellasChina - Shenyang
5 programs
1
2
2
E10030Phase 31 trial
E10030Phase 33 trials
E10030 plus LucentisPhase 21 trial
Fovista®Phase 22 trials
volociximabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT00782093Completed63Est. Jun 2012
NCT01089517Completed449Est. Jun 2012
NCT02387957Terminated63Est. Jan 2017
+5 more trials
Outlook Therapeutics
4 programs
4
bevacizumabPhase 3Monoclonal Antibody1 trial
bevacizumabPhase 3Monoclonal Antibody1 trial
bevacizumabPhase 3Monoclonal Antibody1 trial
bevacizumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT04516278CompletedEst. Feb 2021
NCT03834753CompletedEst. Jul 2021
NCT05112861Active Not RecruitingEst. Mar 2025
+1 more trials
Genentech
GenentechCA - Oceanside
2 programs
1
ranibizumabPhase 2/3Monoclonal Antibody1 trial
Conjunctival and nasopharyngeal swabsN/A1 trial
Active Trials
NCT02126423Completed40Est. Sep 2014
NCT00590694Completed15Est. Dec 2009
S
SantenCA - Emeryville
6 programs
3
3
2.0 mg DE-122 Injectable Solution + LucentisPhase 21 trial
DE-120Phase 21 trial
Sirolimus in combination with ranibizumabPhase 2Monoclonal Antibody1 trial
0.5 mg of DE-122Phase 1/21 trial
DE-120Phase 1/21 trial
+1 more programs
Active Trials
NCT02555306Completed12Est. Aug 2017
NCT02022501Completed10Est. Apr 2016
NCT00712491Terminated20Est. Mar 2010
+3 more trials
Regeneron
RegeneronTARRYTOWN, NY
2 programs
1
Intravitreal aflibercept injectionPhase 21 trial
Intravitreal Aflibercept InjectionN/A1 trial
Active Trials
NCT01773954Completed40Est. Mar 2016
NCT02462889Completed128Est. Mar 2019
ANI Pharmaceuticals
1 program
1
Fluocinolone AcetonidePhase 21 trial
Active Trials
NCT00695318Terminated
Pfizer
PfizerNEW YORK, NY
2 programs
1
1
AG-013,958Phase 1/21 trial
PF-04523655Phase 11 trial
Active Trials
NCT00725686Completed54Est. Nov 2010
NCT00090532Terminated155Est. Aug 2006
Alcon
AlconFORT WORTH, TX
3 programs
2
CLG561Phase 11 trial
LHA510 Ophthalmic SuspensionPhase 11 trial
The Natural History of Geographic Atrophy Progression (GAP) StudyN/A1 trial
Active Trials
NCT00599846Terminated1,000
NCT01835015Completed50Est. Nov 2014
NCT02076919Completed110Est. Jun 2014
Oxford Biomedica
Oxford BiomedicaMA - Bedford
1 program
1
RetinoStatPhase 1Small Molecule1 trial
Active Trials
NCT01678872Active Not Recruiting18Est. Mar 2029
NV
Notal VisionVA - Manassas
4 programs
FORESEE HOMEN/A1 trial
Foresee HomeN/A1 trial
Macular Thickness Measurements Using Retinal-thickness OCTN/A1 trial
Notal OCTN/A1 trial
Active Trials
NCT01083147CompletedEst. Sep 2010
NCT05690880Active Not RecruitingEst. Dec 2027
NCT03030729CompletedEst. Jan 2018
+1 more trials
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
3 programs
DiagnosticsN/A1 trial
Natural history studyN/A1 trial
Streetlab VRN/A1 trial
Active Trials
NCT03935126Terminated3Est. May 2020
NCT05963646Completed30Est. Dec 2023
NCT06619405Recruiting100Est. Dec 2027
OcuDyne
1 program
OPTiC SystemN/A1 trial
Active Trials
NCT05091476CompletedEst. Oct 2024
Apellis Pharmaceuticals
Apellis PharmaceuticalsAustralia - Hawthorn East
1 program
Virtual RealityN/A1 trial
Active Trials
NCT06241625UnknownEst. Jul 2024
Globus Medical
Globus MedicalAUDUBON, PA
1 program
not enriched eggN/A1 trial
Active Trials
NCT00527553CompletedEst. Feb 2008

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
NovartisRanibizumab 0.5 mg
Bausch + Lombpegaptanib sodium injection
NovartisVerteporfin for injection
Outlook Therapeuticsbevacizumab
Outlook Therapeuticsbevacizumab
Outlook Therapeuticsbevacizumab
Outlook Therapeuticsbevacizumab
AstellasE10030
AstellasE10030
AstellasE10030
Genentechranibizumab
NovartisIptacopan
Santen2.0 mg DE-122 Injectable Solution + Lucentis
AstellasFovista®
RegeneronIntravitreal aflibercept injection

Showing 15 of 44 trials with date data

Clinical Trials (44)

Total enrollment: 5,414 patients across 44 trials

NCT02130024NovartisRanibizumab 0.5 mg

A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients

Start: Apr 2014Est. completion: Nov 2017281 patients
Phase 4Completed
NCT01573572Bausch + Lombpegaptanib sodium injection

Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium

Start: Apr 2010Est. completion: Nov 2019131 patients
Phase 4Completed
NCT00135837NovartisVerteporfin for injection

Photodynamic Therapy in Occult-Only Lesions (POOL)

Start: Jun 2003202 patients
Phase 4Completed
NCT05112861Outlook Therapeuticsbevacizumab

A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders

Start: Nov 2021Est. completion: Mar 2025
Phase 3Active Not Recruiting
NCT04516278Outlook Therapeuticsbevacizumab

A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders

Start: Oct 2020Est. completion: Feb 2021
Phase 3Completed
NCT03834753Outlook Therapeuticsbevacizumab

A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Start: Jun 2019Est. completion: Jul 2021
Phase 3Completed
NCT03844074Outlook Therapeuticsbevacizumab

A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Start: Oct 2018Est. completion: Aug 2020
Phase 3Completed
NCT01940887AstellasE10030

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy

Start: May 2014Est. completion: Sep 2017645 patients
Phase 3Terminated
NCT01944839AstellasE10030

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy

Start: Aug 2013Est. completion: Dec 2016619 patients
Phase 3Terminated
NCT01940900AstellasE10030

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy

Start: Aug 2013Est. completion: Dec 2016627 patients
Phase 3Terminated
NCT00590694Genentechranibizumab

Lucentis for Age-related Macular Degeneration Pigment Epithelial Detachments

Start: Oct 2006Est. completion: Dec 200915 patients
Phase 2/3Completed
NCT05230537NovartisIptacopan

A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration

Start: Feb 2022Est. completion: Oct 2026170 patients
Phase 2Active Not Recruiting
NCT03211234Santen2.0 mg DE-122 Injectable Solution + Lucentis

Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects

Start: Jul 2017Est. completion: Jan 202076 patients
Phase 2Completed
NCT02387957AstellasFovista®

A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)

Start: Apr 2016Est. completion: Jan 201763 patients
Phase 2Terminated
NCT02462889RegeneronIntravitreal aflibercept injection

IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD

Start: Jun 2015Est. completion: Mar 2019128 patients
Phase 2Completed
NCT02401945SantenDE-120

A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration

Start: Apr 2015Est. completion: Oct 201616 patients
Phase 2Completed
NCT02214628AstellasFovista®

Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD

Start: Jul 2014Est. completion: Dec 2016101 patients
Phase 2Terminated
NCT01089517AstellasE10030 plus Lucentis

A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration

Start: Mar 2010Est. completion: Jun 2012449 patients
Phase 2Completed
NCT00695318ANI PharmaceuticalsFluocinolone Acetonide

Fluocinolone Acetonide Intravitreal Inserts in Geographic Atrophy

Start: Dec 2008
Phase 2Terminated
NCT00766337SantenSirolimus in combination with ranibizumab

Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration

Start: Dec 2008Est. completion: Mar 201062 patients
Phase 2Terminated
NCT00140803NovartisVisudyne

Study Of Combined VISUDYNE Therapy With Kenalog In CNV Secondary To Age-Related Macular Degeneration

Start: Oct 2003Est. completion: Jan 2007106 patients
Phase 2Completed
NCT02555306Santen0.5 mg of DE-122

A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration

Start: Sep 2015Est. completion: Aug 201712 patients
Phase 1/2Completed
NCT02022501SantenDE-120

A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular Degeneration

Start: Jan 2014Est. completion: Apr 201610 patients
Phase 1/2Completed
NCT00712491SantenSirolimus

Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration

Start: Sep 2008Est. completion: Mar 201020 patients
Phase 1/2Terminated
NCT00090532PfizerAG-013,958

A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration

Start: Jan 2004Est. completion: Aug 2006155 patients
Phase 1/2Terminated
NCT02076919AlconLHA510 Ophthalmic Suspension

First-in-Human Study of LHA510 in Elderly Subjects and Patients With Age-Related Macular Degeneration

Start: Feb 2014Est. completion: Jun 2014110 patients
Phase 1Completed
NCT01835015AlconCLG561

Pharmacokinetics of CLG561 in Patients With Advanced Age-Related Macular Degeneration

Start: May 2013Est. completion: Nov 201450 patients
Phase 1Completed
NCT01678872Oxford BiomedicaRetinoStat

A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration

Start: Aug 2012Est. completion: Mar 202918 patients
Phase 1Active Not Recruiting
NCT00782093Astellasvolociximab

A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration

Start: Oct 2008Est. completion: Jun 201263 patients
Phase 1Completed
NCT00569140AstellasE10030

A Phase 1, Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects With Neovascular Age-Related Macular Degeneration

Start: Dec 2007Est. completion: Dec 200818 patients
Phase 1Completed
NCT00725686PfizerPF-04523655

Study of PF-04523655 (REDD14NP) In Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (Wet AMD)

Start: Feb 2007Est. completion: Nov 201054 patients
Phase 1Completed
NCT06619405Boehringer IngelheimStreetlab VR

AMD and Validation Rod-Meditated Dark Adaptation With Everyday Task Performance

Start: Aug 2025Est. completion: Dec 2027100 patients
N/ARecruiting
NCT05091476OcuDyneOPTiC System

OcuDyne System in the Treatment of AMD

Start: Feb 2023Est. completion: Oct 2024
N/ACompleted
NCT05690880Notal VisionForesee Home

ForeseeHome NRich Registry

Start: Dec 2022Est. completion: Dec 2027
N/AActive Not Recruiting
NCT06241625Apellis PharmaceuticalsVirtual Reality

Virtual Reality Based Vision Test in Patients With AMD

Start: Oct 2022Est. completion: Jul 2024
N/AUnknown
NCT05963646Boehringer IngelheimNatural history study

Optical Coherence Tomography and Microperimetry Biomarker Evaluation in Patients With Geographic Atrophy Study

Start: Mar 2021Est. completion: Dec 202330 patients
N/ACompleted
NCT03935126Boehringer IngelheimDiagnostics

Global Atrophie Biomarker Evaluation Study (GABiE)

Start: May 2019Est. completion: May 20203 patients
N/ATerminated
NCT03030729Notal VisionMacular Thickness Measurements Using Retinal-thickness OCT

Macular Thickness Measurements Using Retinal-thickness OCT

Start: Mar 2017Est. completion: Jan 2018
N/ACompleted
NCT03374020Notal VisionNotal OCT

Retinal Imaging Using NOTAL-OCT

Start: Jan 2017Est. completion: Dec 2018
N/ACompleted
NCT02126423GenentechConjunctival and nasopharyngeal swabs

Resistance to Antibiotics in Patients Receiving Eye Injections

Start: May 2014Est. completion: Sep 201440 patients
N/ACompleted
NCT01773954RegeneronIntravitreal Aflibercept Injection

Repeated Eye Injections of Aflibercept for Treatment of Wet Age Related Macular Degeneration

Start: Feb 2013Est. completion: Mar 201640 patients
N/ACompleted
NCT01083147Notal VisionFORESEE HOME

Age-Related Macular Degeneration (AMD) - Beta Study Telemedicine Assessment

Start: Oct 2009Est. completion: Sep 2010
N/ACompleted
NCT00599846AlconThe Natural History of Geographic Atrophy Progression (GAP) Study

The Natural History of Geographic Atrophy Progression (GAP) Study

Start: Dec 20071,000 patients
N/ATerminated
NCT00527553Globus Medicalnot enriched egg

The Effect of Eggs and Egg Products on Macular Pigment

Start: Oct 2007Est. completion: Feb 2008
N/ACompleted

Related Jobs in Ophthalmology

Lead Data Manager

Genomics
Remote
4h ago

Cleanroom and Laboratory Technician

SAB BIO
4h ago

Product Specialist

Johnson & Johnson
Hangzhou, Zhejiang, China
20h ago

BM 喀什 PSR HY

Johnson & Johnson
Urumqi, Xinjiang, China
20h ago

Site Delivery Leader MLL

Johnson & Johnson
Gent, East Flanders, Belgium
20h ago

Clinical Operations Manager

Johnson & Johnson
Irvine, California, United States of America
20h ago
$117K - $201K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 5,414 patients
17 companies competing in this space

Related Indications

Myopia(127)Cataract(116)Open-Angle Glaucoma(102)Glaucoma(92)Dry Eye(74)Dry Eye Disease(43)Neovascular Age-related Macular Degeneration(40)Macular Degeneration(37)Diabetic Retinopathy(25)Cataracts(22)